Related references
Note: Only part of the references are listed.Venetoclax-ponatinib for T315I/compound-mutated Ph plus acute lymphoblastic leukemia
Huafeng Wang et al.
BLOOD CANCER JOURNAL (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicholas J. Short et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
Michele Massimino et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Impact of frontline treatment approach on outcomes of myeloid blast phase CML
Kapil Saxena et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis
Sha Jin et al.
CLINICAL CANCER RESEARCH (2020)
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Abhishek Maiti et al.
ACTA HAEMATOLOGICA (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia
Yasmin Abaza et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
J. F. Seymour et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Prognostic Factors and Survival Outcomes in Patients With Chronic Myeloid Leukemia in Blast Phase in the Tyrosine Kinase Inhibitor Era: Cohort Study of 477 Patients
Preetesh Jain et al.
CANCER (2017)
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia
Jessica T. Leonard et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Bing Z. Carter et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Yves Chalandon et al.
BLOOD (2015)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era
Hiroaki Shimizu et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
J. M. Bogenberger et al.
LEUKEMIA (2014)
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
Twee Tsao et al.
ANNALS OF HEMATOLOGY (2012)
Philadelphia-Positive Acute Lymphoblastic Leukemia-Is Bone Marrow Transplant Still Necessary?
Adele K. Fielding
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2011)
Philadelphia chromosome-positive acute myeloid leukemia - A rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis
Chad P. Soupir et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2007)
Role of tyrosine kinase inhibitors in cancer therapy
A Arora et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature
YK Keung et al.
LEUKEMIA RESEARCH (2004)
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
NP Shah et al.
CANCER CELL (2002)
Share Paper
